• Publications
  • Influence
STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia
Background Cachexia, or weight loss despite adequate nutrition, significantly impairs quality of life and response to therapy in cancer patients. In cancer patients, skeletal muscle wasting, weightExpand
  • 243
  • 22
  • PDF
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Cachexia, the metabolic dysregulation leading to sustained loss of muscle and adipose tissue, is a devastating complication of cancer and other chronic diseases. Interleukin-6 and related cytokinesExpand
  • 239
  • 17
  • PDF
IGF-1 is downregulated in experimental cancer cachexia.
Cancer cachexia is characterized by skeletal muscle wasting that is mainly supported by hypercatabolism. Muscle atrophy has been suggested to depend on impaired IGF-1 signal transduction pathway. TheExpand
  • 137
  • 10
  • PDF
Muscle myostatin signalling is enhanced in experimental cancer cachexia
Background/Aims   Myostatin belongs to the transforming growth factor‐β superfamily and negatively regulates skeletal muscle mass. Its deletion induces muscle overgrowth, while, on the contrary, itsExpand
  • 155
  • 7
Muscle atrophy in experimental cancer cachexia: Is the IGF‐1 signaling pathway involved?
Skeletal muscle wasting, one of the main features of cancer cachexia, is associated with marked protein hypercatabolism, and has suggested to depend also on impaired IGF‐1 signal transductionExpand
  • 86
  • 6
STAT3 in the systemic inflammation of cancer cachexia.
Weight loss is diagnostic of cachexia, a debilitating syndrome contributing mightily to morbidity and mortality in cancer. Most research has probed mechanisms leading to muscle atrophy and adiposeExpand
  • 95
  • 4
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.
Duchenne muscular dystrophy (DMD) and its milder allelic variant, Becker muscular dystrophy (BMD), result from mutations of the dystrophin gene and lead to progressive muscle deterioration. EnhancedExpand
  • 62
  • 4
  • PDF
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs
Cachexia affects the majority of cancer patients, with currently no effective treatments. Cachexia is defined by increased fatigue and loss of muscle function resulting from muscle and fat depletion.Expand
  • 66
  • 3
  • PDF
Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia
Cachexia frequently occurs in women with advanced ovarian cancer (OC), along with enhanced inflammation. Despite being responsible for one third of all cancer deaths, cachexia is generallyExpand
  • 22
  • 3
  • PDF
Assessment of muscle mass and strength in mice.
Muscle weakness is an important phenotype of many diseases that is linked to impaired locomotion and increased mortality. The force that a muscle can generate is determined predominantly by muscleExpand
  • 58
  • 2